AI for Selection of Combination Therapies
The post AI for Selection of Combination Therapies appeared first on Bioxcel.
BioXcel Appoints Dr. Peter Mueller as Chairman of Scientific Advisory Board
SAB to Guide Advancement of Multiple Therapeutic Programs BRANFORD, Conn., Oct. 12, 2016 (GLOBE NEWSWIRE) — BioXcel, a privately held biopharmaceutical company based in Connecticut, today announced the appointment of Dr. Peter Mueller, Ph.D. as Chairman of its Scientific Advisory Board (“SAB”), which will serve as a strategic resource to the Company as it advances … Continue reading BioXcel Appoin...
BioXcel Appoints Eric K. Rowinsky, M.D. to its Board of Directors
Appointment of industry leader brings broad R&D Experience to Board BRANFORD, Conn., Jan. 05, 2017 (GLOBE NEWSWIRE) — BioXcel, a privately held biopharmaceutical company pioneering the integration of big data analytics and machine learning-based artificial intelligence (AI) with drug development expertise to advance the next wave of medicines, today announced the appointment of Dr. Eric … Continue...